Related Experiment Videos

Evaluation of coronary revascularization for ischemic heart disease: in the consecutive 200 cases

H Hirose1, S Nakano, H Matsuda

  • 1Department of Surgery, Osaka University Medical School, Japan.

Insights

Coronary revascularization showed no operative deaths in the second 100 patients, even with high-risk factors. Long-term follow-up revealed improved exercise tolerance and high graft patency rates.

Area of Science:

  • Cardiology
  • Cardiac Surgery

Background:

  • Coronary revascularization is increasingly performed in older patients with significant comorbidities.
  • Assessing outcomes in this high-risk population is crucial for surgical decision-making.

Purpose of the Study:

  • To evaluate the safety and efficacy of elective simple coronary revascularization in a consecutive patient cohort.
  • To analyze perioperative and long-term outcomes, including mortality, graft patency, and functional status.

Main Methods:

  • Retrospective analysis of 200 consecutive patients undergoing elective simple coronary revascularization.
  • Inclusion of patients with high-risk factors such as low left ventricular ejection fraction (LVEF) and multi-vessel disease.
  • Assessment of perioperative outcomes, 7-year survival, graft patency, and exercise tolerance.

Main Results:

  • No operative deaths occurred in the second 100 patients, compared to the first 100.
  • Calcium antagonists effectively managed spastic angina perioperatively.
  • No cardiac deaths were observed during the 7-year follow-up.
  • Improved exercise tolerance was noted, even in patients with preoperative low LVEF.
  • Graft patency rates were 92% at an average follow-up of 11 months for both saphenous vein grafts and internal mammary artery grafts (IMAG).

Conclusions:

  • Elective simple coronary revascularization is a safe procedure with excellent long-term outcomes, even in high-risk patients.
  • Internal mammary artery grafts demonstrate comparable patency and flow characteristics to saphenous vein grafts.
  • Management of comorbidities like hyperlipidemia and diabetes is essential for preventing graft occlusion and disease progression.

Related Concept Videos